STOCK TITAN

GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

GRAIL (Nasdaq: GRAL) has announced its upcoming participation at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The company's management will deliver a presentation on Thursday, November 21 at 11:00 a.m. ET. The event will be accessible via live and replay webcasts through GRAIL's investor relations website section at investors.grail.com, with recordings available for at least 30 days following the presentation.

GRAIL (Nasdaq: GRAL) ha annunciato la sua prossima partecipazione al Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum a New York. La dirigenza dell'azienda farà una presentazione giovedì 21 novembre alle 11:00 ET. L'evento sarà accessibile tramite webcast in diretta e registrata attraverso la sezione delle relazioni con gli investitori di GRAIL sul sito investors.grail.com, con registrazioni disponibili per almeno 30 giorni dopo la presentazione.

GRAIL (Nasdaq: GRAL) ha anunciado su próxima participación en el Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum en Nueva York. La dirección de la empresa realizará una presentación el jueves 21 de noviembre a las 11:00 a.m. ET. El evento será accesible a través de webcast en vivo y grabaciones a través de la sección de relaciones con inversores de GRAIL en investors.grail.com, con grabaciones disponibles durante al menos 30 días después de la presentación.

GRAIL (Nasdaq: GRAL)는 뉴욕에서 열리는 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum에 곧 참여할 것이라고 발표했습니다. 회사 경영진은 11월 21일 목요일 오전 11시(ET)에 프레젠테이션을 진행할 예정입니다. 이 이벤트는 investors.grail.com의 투자자 관계 웹사이트 섹션을 통해 실시간 및 재생 웹캐스트로 접근할 수 있으며, 프레젠테이션 이후 최소 30일 간 녹화본을 이용할 수 있습니다.

GRAIL (Nasdaq: GRAL) a annoncé sa prochaine participation au Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum à New York. La direction de l'entreprise fera une présentation le jeudi 21 novembre à 11h00 ET. L'événement sera accessible via des webinaires en direct et en rediffusion sur la section des relations avec les investisseurs de GRAIL à investors.grail.com, avec des enregistrements disponibles pendant au moins 30 jours après la présentation.

GRAIL (Nasdaq: GRAL) hat seine bevorstehende Teilnahme am Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York angekündigt. Die Unternehmensführung wird am Donnerstag, den 21. November um 11:00 Uhr ET eine Präsentation halten. Die Veranstaltung wird über Live- und Replay-Webcasts über den Bereich für Investor Relations von GRAIL unter investors.grail.com zugänglich sein, wobei die Aufzeichnungen mindestens 30 Tage nach der Präsentation verfügbar sind.

Positive
  • None.
Negative
  • None.

MENLO PARK, Calif., Nov. 4, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, Nov. 21 at 11:00 a.m. ET. 

Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-302295742.html

SOURCE GRAIL, Inc.

FAQ

When is GRAIL (GRAL) presenting at the Canaccord Genuity Forum in November 2024?

GRAIL (GRAL) will present at the Canaccord Genuity Forum on Thursday, November 21, 2024, at 11:00 a.m. ET in New York.

How can investors watch GRAIL's (GRAL) Canaccord Genuity Forum presentation?

Investors can watch the presentation through live and replay webcasts available in the investor relations section of GRAIL's website at investors.grail.com.

How long will GRAIL's (GRAL) Canaccord Genuity presentation replay be available?

The webcast replay will be archived and available for at least 30 days after the event.

What type of forum is GRAIL (GRAL) presenting at in November 2024?

GRAIL is presenting at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, which focuses on medical technology and healthcare services.

GRAIL, Inc.

NASDAQ:GRAL

GRAL Rankings

GRAL Latest News

GRAL Stock Data

735.02M
28.98M
13.75%
67.1%
11.25%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
MENLO PARK